Abstract
Context:
The understanding of the potential role of betatrophin in human metabolic disorders is a current challenge.
Objective:
The present research evaluated circulating betatrophin levels in obese patients with metabolic syndrome (MetSyn) features under energy-restricted weight-loss programs and in normal weight in order to establish the putative interplay between the levels of this hormone, diet and metabolic risk factors linked to obesity and associated comorbidities.
Subjects and Methods:
One hundred forty-three participants were enrolled in the study (95 obese–MetSyn; age 49.5±9.4 years; body mass index (BMI) 35.7±4.5 kg m–2 and 48 normal weight; age 35.71±8.8 years; BMI 22.9±2.2 kg m–2). A nutritional therapy consisting in two hypocaloric strategies (control diet based on the AHA recommendations and the RESMENA (MEtabolic Syndrome REduction in Navarra) diet, a novel dietary program with changes in the macronutrient distribution) was only prescribed to obese–MetSyn participants who were randomly allocated to the dietary strategies. Dietary records, anthropometrical and biochemical variables as well as betatrophin levels were analyzed before (pre-intervention, week 0), at 8 weeks (post-intervention, week 8) and after 4 additional months of self-control period (follow-up, week 24).
Results:
Betatrophin levels were higher in obese–MetSyn patients than normal-weight subjects (1.24±0.43 vs 0.97±0.69 ng ml–1, respectively, P=0.012), and levels were positively associated with body composition, metabolic parameters, leptin and irisin in all participants at baseline. Notably, low pre-intervention (week 0) betatrophin levels in obese patients were significantly associated with higher dietary-induced changes in atherogenic risk factors after 8 weeks. Moreover, protein intake, especially proteins from animal sources, was an independent determinant of betatrophin levels after dietary treatment (B=–0.27; P=0.012).
Conclusions:
Betatrophin is elevated in obese patients with MetSyn features and is associated with poorer nutritional outcomes of adiposity and dyslipidemia traits after a weight-loss program. Dietary protein intake could be a relevant modulator of betatrophin secretion and activity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gutierrez-Fisac JL, Guallar-Castillon P, Leon-Munoz LM, Graciani A, Banegas JR, Rodriguez-Artalejo F . Prevalence of general and abdominal obesity in the adult population of Spain, 2008-2010: the ENRICA study. Obes Rev 2011; 13: 388–392.
Bray GA, Bellanger T . Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 2006; 29: 109–117.
Eckel RH, Grundy SM, Zimmet PZ . The metabolic syndrome. Lancet 2005; 365: 1415–1428.
Chaput JP, Tremblay A . Current and novel approaches to the drug therapy of obesity. Eur J Clin Pharmacol 2006; 62: 793–803.
Crujeiras AB, Carreira MC, Casanueva FF . Obesity and the future. New problems and new solutions. Endocrinol Nutr 2013; 60: 33–35.
Friedman JM . The function of leptin in nutrition, weight, and physiology. Nutr Rev 2002; 60: S1–S14; discussion S68-S84, 85-88.
Al-Massadi O, Crujeiras AB, Gonzalez RC, Pardo M, Dieguez C, Casanueva FF et al. Age, sex, and lactating status regulate ghrelin secretion and GOAT mRNA levels from isolated rat stomach. Am J Physiol Endocrinol Metab 2010; 299: E341–E350.
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K . Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656–660.
Wynne K, Stanley S, Bloom S . The gut and regulation of body weight. J Clin Endocrinol Metab 2004; 89: 2576–2582.
Pedersen BK . Muscles and their myokines. J Exp Biol 2011; 214: 337–346.
Yi P, Park JS, Melton DA . Betatrophin: a hormone that controls pancreatic beta cell proliferation. Cell 2013; 153: 747–758.
Fu Z, Berhane F, Fite A, Seyoum B, Abou-Samra AB, Zhang R . Elevated circulating lipasin/betatrophin in human type 2 diabetes and obesity. Sci Rep 2014; 4: 5013.
Fu Z, Yao F, Abou-Samra AB, Zhang R . Lipasin, thermoregulated in brown fat, is a novel but atypical member of the angiopoietin-like protein family. Biochem Biophys Res Commun 2013; 430: 1126–1131.
Quagliarini F, Wang Y, Kozlitina J, Grishin NV, Hyde R, Boerwinkle E et al. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci USA 2012; 109: 19751–19756.
Ren G, Kim JY, Smas CM . Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism. Am J Physiol Endocrinol Metab 2012; 303: E334–E351.
Wang Y, Quagliarini F, Gusarova V, Gromada J, Valenzuela DM, Cohen JC et al. Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis. Proc Natl Acad Sci USA 2013; 110: 16109–16114.
Zhang R . Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. Biochem Biophys Res Commun 2012; 424: 786–792.
Chen X, Lu P, He W, Zhang J, Liu L, Yang Y et al. Circulating betatrophin levels are increased in patients with type 2 diabetes and associated with insulin resistance. J Clin Endocrinol Metab 2015; 100: E96–E100.
Espes D, Lau J, Carlsson PO . Increased circulating levels of betatrophin in individuals with long-standing type 1 diabetes. Diabetologia 2014; 57: 50–53.
Hu H, Sun W, Yu S, Hong X, Qian W, Tang B et al. Increased circulating levels of betatrophin in newly diagnosed type 2 diabetic patients. Diabetes Care 2014; 37: 2718–2722.
Wu S, Gao H, Ma Y, Fu L, Zhang C, Luo X . Characterisation of betatrophin concentrations in childhood and adolescent obesity and insulin resistance. Pediatr Diabetes 2014; e-pub ahead of print 21 November 2014; doi:10.1111/pedi.12233.
Abu-Farha M, Abubaker J, Al-Khairi I, Cherian P, Noronha F, Hu FB et al. Higher plasma betatrophin/ANGPTL8 level in Type 2 Diabetes subjects does not correlate with blood glucose or insulin resistance. Sci Rep 2015; 5: 10949.
Fenzl A, Itariu BK, Kosi L, Fritzer-Szekeres M, Kautzky-Willer A, Stulnig TM et al. Circulating betatrophin correlates with atherogenic lipid profiles but not with glucose and insulin levels in insulin-resistant individuals. Diabetologia 2014; 57: 1204–1208.
Guo K, Lu J, Yu H, Zhao F, Pan P, Zhang L et al. Serum betatrophin concentrations are significantly increased in overweight but not in obese or type 2 diabetic individuals. Obesity (Silver Spring) 2015; 23: 793–797.
Gomez-Ambrosi J, Pascual E, Catalan V, Rodriguez A, Ramirez B, Silva C et al. Circulating betatrophin concentrations are decreased in human obesity and type 2 diabetes. J Clin Endocrinol Metab 2014; 99: E2004–E2009.
Alberti KG, Zimmet P, Shaw J . The metabolic syndrome—a new worldwide definition. Lancet 2005; 366: 1059–1062.
Lopez-Legarrea P, de la Iglesia R, Abete I, Bondia-Pons I, Navas-Carretero S, Forga L et al. Short-term role of the dietary total antioxidant capacity in two hypocaloric regimes on obese with metabolic syndrome symptoms: the RESMENA randomized controlled trial. Nutr Metab (Lond) 2013; 10: 22.
de la Iglesia R, Lopez-Legarrea P, Celada P, Sanchez-Muniz FJ, Martinez JA, Zulet MA . Beneficial effects of the RESMENA dietary pattern on oxidative stress in patients suffering from metabolic syndrome with hyperglycemia are associated to dietary TAC and fruit consumption. Int J Mol Sci 2013; 14: 6903–6919.
Crujeiras AB, Parra D, Goyenechea E, Abete I, Martinez JA . Tachyphylaxis effects on postprandial oxidative stress and mitochondrial-related gene expression in overweight subjects after a period of energy restriction. Eur J Nutr 2009; 48: 341–347.
Friedewald WT, Levy RI, Fredrickson DS . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.
Crujeiras AB, Goyenechea E, Abete I, Lage M, Carreira MC, Martinez JA et al. Weight regain after a diet-induced loss is predicted by higher baseline leptin and lower ghrelin plasma levels. J Clin Endocrinol Metab 2010; 95: 5037–5044.
Martinez-Gonzalez MA, Lopez-Fontana C, Varo JJ, Sanchez-Villegas A, Martinez JA . Validation of the Spanish version of the physical activity questionnaire used in the Nurses' Health Study and the Health Professionals' Follow-up Study. Public Health Nutr 2005; 8: 920–927.
Li Y, Teng C . Angiopoietin-like proteins 3, 4 and 8: regulating lipid metabolism and providing new hope for metabolic syndrome. J Drug Target 2014; 22: 679–687.
Tang T, Li L, Tang J, Li Y, Lin WY, Martin F et al. A mouse knockout library for secreted and transmembrane proteins. Nat Biotechnol 2010; 28: 749–755.
Fu Z, Abou-Samra AB, Zhang R . An explanation for recent discrepancies in levels of human circulating betatrophin. Diabetologia 2014; 57: 2232–2234.
Astrup A, Raben A, Geiker N . The role of higher protein diets in weight control and obesity-related comorbidities. Int J Obes (Lond) 2014; 39: 721–726.
Westerterp-Plantenga MS, Lemmens SG, Westerterp KR . Dietary protein - its role in satiety, energetics, weight loss and health. Br J Nutr 2012; 108: S105–S112.
Larsen TM, Dalskov SM, van Baak M, Jebb SA, Papadaki A, Pfeiffer AF et al. Diets with high or low protein content and glycemic index for weight-loss maintenance. N Engl J Med 2010; 363: 2102–2113.
Alkerwi A, Sauvageot N, Buckley JD, Donneau AF, Albert A, Guillaume M et al. The potential impact of animal protein intake on global and abdominal obesity: evidence from the Observation of Cardiovascular Risk Factors in Luxembourg (ORISCAV-LUX) study. Public Health Nutr 2015; 18: 1831–1838.
Lin Y, Mouratidou T, Vereecken C, Kersting M, Bolca S, de Moraes AC et al. Dietary animal and plant protein intakes and their associations with obesity and cardio-metabolic indicators in European adolescents: the HELENA cross-sectional study. Nutr J 2015; 14: 10.
Lopez-Legarrea P, de la Iglesia R, Abete I, Navas-Carretero S, Martinez JA, Zulet MA . The protein type within a hypocaloric diet affects obesity-related inflammation: the RESMENA project. Nutrition 2014; 30: 424–429.
Gogebakan O, Kohl A, Osterhoff MA, van Baak MA, Jebb SA, Papadaki A et al. Effects of weight loss and long-term weight maintenance with diets varying in protein and glycemic index on cardiovascular risk factors: the diet, obesity, and genes (DiOGenes) study: a randomized, controlled trial. Circulation 2011; 124: 2829–2838.
Acknowledgements
We thank all the subjects who participated in this study and the research group implicated in the RESMENA project, especially the people who performed the field work (R de la Iglesia, P Lopez-Legarrea, S Perez and BE Martinez de Morentin). This work was supported by grants from the Fondo de Investigacion Sanitaria, INTRASALUD programme (PI10/02464), Instituto de Salud Carlos III (ISCIII), and the Health Department of the Government of Navarra (48/2009) and Xunta de Galicia, Spain and Linea Especial 'Nutrition, Obesity and Health' (University of Navarra LE/97). CIBERobn is an initiative of the ISCIII, Spain.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on International Journal of Obesity website
Supplementary information
Rights and permissions
About this article
Cite this article
Crujeiras, A., Zulet, M., Abete, I. et al. Interplay of atherogenic factors, protein intake and betatrophin levels in obese–metabolic syndrome patients treated with hypocaloric diets. Int J Obes 40, 403–410 (2016). https://doi.org/10.1038/ijo.2015.206
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ijo.2015.206
This article is cited by
-
Circulating ANGPTL8 levels and risk of kidney function decline: Results from the 4C Study
Cardiovascular Diabetology (2021)
-
ANGPTL8 roles in proliferation, metabolic diseases, hypothyroidism, polycystic ovary syndrome, and signaling pathways
Molecular Biology Reports (2021)
-
New insights into ANGPTL8 in modulating the development of cardio-metabolic disorder diseases
Molecular Biology Reports (2021)
-
Triglyceride-mediated influence of serum angiopoietin-like protein 8 on subclinical atherosclerosis in type 2 diabetic patients: results from the GDMD study in China
Cardiovascular Diabetology (2018)
-
Plasma FGF21 levels in obese patients undergoing energy-restricted diets or bariatric surgery: a marker of metabolic stress?
International Journal of Obesity (2017)